PathAI Integrates Multiple AI Pathology Solutions into AISight Platform to Enhance Diagnostic Capabilities

PathAI announced the integration of several AI products from leading digital pathology companies including Deep Bio, DoMore Diagnostics, Paige, and Visiopharm into its AISight Image Management System. This collaboration reinforces PathAI's commitment to offering the most versatile, reliable, and interoperable IMS on the market by providing algorithms from these developers directly within its platform.

Sun Woo Kim, CEO of Deep Bio, stated that integrating Deep Bio's DeepDx Prostate with PathAI's AISight platform marks an important step forward in prostate cancer diagnostics, combining AI-driven pathology insights with robust image management capabilities to support streamlined workflows. This collaboration brings advanced data-driven tools to the hands of pathologists globally, enabling more efficient pathology processes and reinforcing commitment to innovation in cancer diagnostics.

Torbjørn Furuseth, Co-Founder and CEO of DoMore Diagnostics, emphasized the shared vision to realize the promise of digital pathology and outcome prediction to improve patient lives worldwide. The AISight platform is set to spearhead innovations in the field and will be a key partner in personalizing cancer treatment with their Histotype Px digital biomarker.

Peter Hamilton, GM of Diagnostics at Paige, noted that the partnership with PathAI represents an important step forward for digital pathology, allowing pathologists to benefit from the best offerings the industry can provide as two leaders in the space combine their solutions.

Michael Grunkin, CEO of Visiopharm, expressed delight in collaborating with PathAI to bring their portfolio of fully automated, zero-click AI-driven diagnostic and translational solutions for breast and lung cancer to a broader audience. This partnership represents an important step toward expanding access to precision pathology on leading platforms with their platform-agnostic technology designed for seamless integration.

Utilizing the AISight IMS, partner laboratories will be able to seamlessly access a diverse portfolio of digital pathology algorithms from leading global AI companies. Through these deep integrations, pathologists will benefit from rich visual support including AI-generated overlays and embedded quantitative results driving differentiated workflows. This integrated user experience will allow labs to realize maximum value from algorithm product usage in their routine lab workflows.

AISight's growing portfolio of algorithms supports various needs including workflow optimization, biomarker quantification, risk stratification, slide quality control, and tumor sufficiency. These integrations are powered by AISight Link, an open API that allows algorithm developers to leverage the platform's advanced features including AI Impressions, Fields of Interest, and comprehensive reporting tools available at https://www.pathai.com/.

Andy Beck, MD, PhD, co-founder and CEO of PathAI, stated that these partnerships are a testament to the commitment to building a robust ecosystem of AI and digital pathology innovators. Through AISight Link, they ensure seamless interoperability between AISight and third-party AI algorithms, as well as integration with Laboratory Information Systems and other essential IT infrastructure in modern pathology labs, collectively driving improvements in patient outcomes.